Announcements Trials

Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1

Conditions

Hemangioma, Capillary 2 Motor Activity 1 Lymphoma 1 Liver Cirrhosis 1 Leukemia 1 Hemangioma 1 Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 346 Cytarabine 282 fludarabine phosphate 203 Methotrexate 186 Filgrastim 159 Busulfan 148 Etoposide 135 Peripheral Blood Stem Cell Transplantation 134 fludarabine 128 Rituximab 119 Radiotherapy 111 Vincristine 102 Cyclosporine 98 Daunorubicin 96 Antilymphocyte Serum 94 Dexamethasone 91 Tacrolimus 86 Mycophenolic Acid 86 Whole-Body Irradiation 81 Melphalan 79 Imatinib Mesylate 69 Idarubicin 67 Granulocyte Colony-Stimulating Factor 66 Mercaptopurine 65 Azacitidine 65 Methylprednisolone 59 Doxorubicin 58 Prednisone 57 Clofarabine 54 sargramostim 53

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Leukemia × Nadolol × Clear all

NCT06643221 2024-10-16

Allo-X

University of Arizona

Phase EARLY_PHASE1 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Motor Activity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡